Literature DB >> 10964951

Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin1.

I Dewachter1, J Van Dorpe, L Smeijers, M Gilis, C Kuipéri, I Laenen, N Caluwaerts, D Moechars, F Checler, H Vanderstichele, F Van Leuven.   

Abstract

Aging of transgenic mice that overexpress the London mutant of amyloid precursor protein (APP/V717I) (Moechars et al., 1999a) was now demonstrated not to affect the normalized levels of alpha- or beta-cleaved secreted APP nor of the beta-C-terminal stubs. This indicated that aging did not markedly disturb either alpha- or beta-secretase cleavage of APP and failed to explain the origin of the massive amounts of amyloid peptides Abeta40 and Abeta42, soluble and precipitated as amyloid plaques in the brain of old APP/V717I transgenic mice. We tested the hypothesis that aging acted on presenilin1 (PS1) to affect gamma-secretase-mediated production of amyloid peptides by comparing aged APP/V717I transgenic mice to double transgenic mice coexpressing human PS1 and APP/V717I. In double transgenic mice with mutant (A246E) but not wild-type human PS1, brain amyloid peptide levels increased and resulted in amyloid plaques when the mice were only 6-9 months old, much earlier than in APP/V717I transgenic mice (12-15 months old). Mutant PS1 increased mainly brain Abeta42 levels, whereas in aged APP/V717I transgenic mice, both Abeta42 and Abeta40 increased. This resulted in a dramatic difference in the Abeta42/Abeta40 ratio of precipitated or plaque-associated amyloid peptides, i.e., 3.11+/-0.22 in double APP/V717I x PS1/A246E transgenic mice compared with 0.43 +/- 0.07 in aged APP/V717I transgenic mice, and demonstrated a clear difference between the effect of aging and the effect of the insertion of a mutant PS1 transgene. In conclusion, we demonstrate that aging did not favor amyloidogenic over nonamyloidogenic processing of APP, nor did it exert a mutant PS1-like effect on gamma-secretase. Therefore, the data are interpreted to suggest that parenchymal and vascular accumulation of amyloid in aging brain resulted from failure to clear the amyloid peptides rather than from increased production.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964951      PMCID: PMC6772965     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  35 in total

1.  Does Alzheimer disease tilt the scales of amyloid degradation versus accumulation?

Authors:  C Glabe
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation.

Authors:  W T Kimberly; W Xia; T Rahmati; M S Wolfe; D J Selkoe
Journal:  J Biol Chem       Date:  2000-02-04       Impact factor: 5.157

3.  Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.

Authors:  K Johnson-Wood; M Lee; R Motter; K Hu; G Gordon; R Barbour; K Khan; M Gordon; H Tan; D Games; I Lieberburg; D Schenk; P Seubert; L McConlogue
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

4.  Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's disease-associated presenilins.

Authors:  B De Strooper; M Beullens; B Contreras; L Levesque; K Craessaerts; B Cordell; D Moechars; M Bollen; P Fraser; P S George-Hyslop; F Van Leuven
Journal:  J Biol Chem       Date:  1997-02-07       Impact factor: 5.157

5.  Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state.

Authors:  Y M Li; M T Lai; M Xu; Q Huang; J DiMuzio-Mower; M K Sardana; X P Shi; K C Yin; J A Shafer; S J Gardell
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

6.  Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1.

Authors:  K Duff; C Eckman; C Zehr; X Yu; C M Prada; J Perez-tur; M Hutton; L Buee; Y Harigaya; D Yager; D Morgan; M N Gordon; L Holcomb; L Refolo; B Zenk; J Hardy; S Younkin
Journal:  Nature       Date:  1996-10-24       Impact factor: 49.962

7.  Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid beta peptides: their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer's disease and cerebral amyloid angiopathy cases.

Authors:  H Barelli; A Lebeau; J Vizzavona; P Delaere; N Chevallier; C Drouot; P Marambaud; K Ancolio; J D Buxbaum; O Khorkova; J Heroux; S Sahasrabudhe; J Martinez; J M Warter; M Mohr; F Checler
Journal:  Mol Med       Date:  1997-10       Impact factor: 6.354

8.  Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo.

Authors:  D R Borchelt; G Thinakaran; C B Eckman; M K Lee; F Davenport; T Ratovitsky; C M Prada; G Kim; S Seekins; D Yager; H H Slunt; R Wang; M Seeger; A I Levey; S E Gandy; N G Copeland; N A Jenkins; D L Price; S G Younkin; S S Sisodia
Journal:  Neuron       Date:  1996-11       Impact factor: 17.173

9.  Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease.

Authors:  H Funato; M Yoshimura; K Kusui; A Tamaoka; K Ishikawa; N Ohkoshi; K Namekata; R Okeda; Y Ihara
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

10.  Additive effects of PS1 and APP mutations on secretion of the 42-residue amyloid beta-protein.

Authors:  M Citron; C B Eckman; T S Diehl; C Corcoran; B L Ostaszewski; W Xia; G Levesque; P St George Hyslop; S G Younkin; D J Selkoe
Journal:  Neurobiol Dis       Date:  1998-08       Impact factor: 5.996

View more
  40 in total

Review 1.  Mouse models of Alzheimer's disease.

Authors:  Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2011-11-28       Impact factor: 4.077

Review 2.  Vaccines for Alzheimer's disease: how close are we?

Authors:  Christopher Janus
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 3.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

4.  Relevance of transgenic mouse models for Alzheimer's disease.

Authors:  Leon M Tai; Juan Maldonado Weng; Mary Jo LaDu; Scott T Brady
Journal:  Prog Mol Biol Transl Sci       Date:  2020-08-24       Impact factor: 3.622

5.  Sex-dependent actions of amyloid beta peptides on hippocampal choline carriers of postnatal rats.

Authors:  Z Kristofiková; J Rícný; I Kozmiková; D Rípová; P Zach; J Klaschka
Journal:  Neurochem Res       Date:  2006-03       Impact factor: 3.996

6.  Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease.

Authors:  Rinaldo Zurbriggen; Mario Amacker; Andreas R Kammer; Nicole Westerfeld; Peter Borghgraef; Fred Van Leuven; Ingrid Van der Auwera; Stefaan Wera
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

Review 7.  Role of ROS and RNS Sources in Physiological and Pathological Conditions.

Authors:  Sergio Di Meo; Tanea T Reed; Paola Venditti; Victor Manuel Victor
Journal:  Oxid Med Cell Longev       Date:  2016-07-12       Impact factor: 6.543

Review 8.  What can rodent models tell us about cognitive decline in Alzheimer's disease?

Authors:  Sabrina Davis; Serge Laroche
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

9.  Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model.

Authors:  An Tanghe; Annelies Termont; Pascal Merchiers; Stephan Schilling; Hans-Ulrich Demuth; Louise Scrocchi; Fred Van Leuven; Gerard Griffioen; Tom Van Dooren
Journal:  Int J Alzheimers Dis       Date:  2010-09-02

Review 10.  Presenilin transgenic mice as models of Alzheimer's disease.

Authors:  Gregory A Elder; Miguel A Gama Sosa; Rita De Gasperi; Dara L Dickstein; Patrick R Hof
Journal:  Brain Struct Funct       Date:  2009-11-18       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.